{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:00:04Z","timestamp":1784116804693,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012306","name":"Universit\u00e0 degli Studi di Trieste","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012306","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Patients diagnosed with coronary artery disease are at a high risk of subsequent cardiovascular events; therefore, secondary prevention in the form of therapeutic lifestyle changes, and drug therapies is vital. This article aims to review potential application of intra-coronary imaging for the evaluation of plaque modifications, induced by medications for secondary prevention for CAD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Intra-coronary imaging provides detailed information on the atherosclerotic plaque which is the primary pathological substrate for the recurrent ischemic cardiovascular events. These modalities can detect features associated with high risk and allow serial in vivo imaging of lesions. Therefore, intravascular imaging tools have been used in landmark studies and played a role in improving our understanding of the disease processes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Changes in size and plaque composition over time can be evaluated by these tools and may help understanding the impact of a treatment. Moreover, surrogate imaging end points can be used when testing new drugs for secondary prevention.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11883-020-00890-4","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T01:03:11Z","timestamp":1602032591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention"],"prefix":"10.1007","volume":"22","author":[{"given":"Ismail Dogu","family":"Kilic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-0736","authenticated-orcid":false,"given":"Enrico","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvin","family":"Kedhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liviu-Nicolae","family":"Ghilencea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Caiazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Abou","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Di Mario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"issue":"21","key":"890_CR1","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.jacc.2010.02.026","volume":"55","author":"SJ Nicholls","year":"2010","unstructured":"Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010;55(21):2399\u2013407.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"890_CR2","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jcin.2011.07.013","volume":"4","author":"MC McDaniel","year":"2011","unstructured":"McDaniel MC, Eshtehardi P, Sawaya FJ, Douglas JS, Samady H. Contemporary clinical applications of coronary intravascular ultrasound. JACC Cardiovasc Interv. 2011;4(11):1155\u201367.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"890_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/eurheartj\/ehs411","volume":"34","author":"E Falk","year":"2013","unstructured":"Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists\u2019 view. Eur Heart J. 2013;34(10):719\u201328.","journal-title":"Eur Heart J"},{"issue":"24","key":"890_CR4","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehv323","volume":"37","author":"C Di Mario","year":"2016","unstructured":"Di Mario C, Moreno PR. Invasive coronary imaging: any role in primary and secondary prevention? Eur Heart J. 2016;37(24):1883\u201390.","journal-title":"Eur Heart J"},{"key":"890_CR5","doi-asserted-by":"crossref","unstructured":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89\u201395.","DOI":"10.1067\/mcp.2001.113989"},{"issue":"1","key":"890_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1157\/13083650","volume":"59","author":"SJ Nicholls","year":"2006","unstructured":"Nicholls SJ, Sipahi I, Tuzcu EM. Assessment of progression and regression of coronary atherosclerosis by intravascular ultrasound. A New Paradigm Shift? Rev Espa\u00f1ola Cardiol (English Ed). 2006;59(1):57\u201366.","journal-title":"Rev Espa\u00f1ola Cardiol (English Ed)"},{"issue":"6","key":"890_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nrd2040","volume":"5","author":"SJ Nicholls","year":"2006","unstructured":"Nicholls SJ, Sipahi I, Schoenhagen P, Crowe T, Tuzcu EM, Nissen SE. Application of intravascular ultrasound in anti-atherosclerotic drug development. Nat Rev Drug Discov. 2006;5(6):485\u201392.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"890_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrd2588","volume":"7","author":"AC Lindsay","year":"2008","unstructured":"Lindsay AC, Choudhury RP. Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov. 2008;7(6):517\u201329.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"890_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/ejechocard\/jer017","volume":"12","author":"M Hartmann","year":"2011","unstructured":"Hartmann M, Huisman J, B\u00f6se D, Jensen LO, Schoenhagen P, Mintz GS, et al. Serial intravascular ultrasound assessment of changes in coronary atherosclerotic plaque dimensions and composition: an update. Eur J Echocardiogr. 2011;12(4):313\u201321.","journal-title":"Eur J Echocardiogr"},{"issue":"8934","key":"890_CR10","first-page":"1383","volume":"344","author":"Group SSSS","year":"1994","unstructured":"Group SSSS. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet. 1994;344(8934):1383\u20139.","journal-title":"Lancet."},{"issue":"20","key":"890_CR11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med. 1995;333(20):1301\u20137.","journal-title":"N Engl J Med"},{"issue":"14","key":"890_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 1996;335(14):1001\u20139.","journal-title":"N Engl J Med"},{"issue":"10","key":"890_CR13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.7326\/0003-4819-119-10-199311150-00002","volume":"119","author":"DH Blankenhorn","year":"1993","unstructured":"Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, et al. Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study (MARS). Ann Intern Med. 1993;119(10):969\u201376.","journal-title":"Ann Intern Med"},{"issue":"6","key":"890_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/00041433-199512000-00010","volume":"6","author":"GR Thompson","year":"1995","unstructured":"Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol. 1995;6(6):386\u20138.","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"890_CR15","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/01.CIR.91.10.2528","volume":"91","author":"JW Jukema","year":"1995","unstructured":"Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The regression growth evaluation statin study (REGRESS). Circulation. 1995;91(10):2528\u201340.","journal-title":"Circulation."},{"issue":"6","key":"890_CR16","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/01.CIR.87.6.1781","volume":"87","author":"BG Brown","year":"1993","unstructured":"Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87(6):1781\u201391.","journal-title":"Circulation."},{"issue":"12","key":"890_CR17","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0002-9149(97)00221-X","volume":"79","author":"T Takagi","year":"1997","unstructured":"Takagi T, Yoshida K, Akasaka T, Hozumi T, Morioka S, Yoshikawa J. Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin. Am J Cardiol. 1997;79(12):1673\u20136.","journal-title":"Am J Cardiol"},{"issue":"4","key":"890_CR18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0735-1097(03)00770-8","volume":"42","author":"M Takano","year":"2003","unstructured":"Takano M, Mizuno K, Yokoyama S, Seimiya K, Ishibashi F, Okamatsu K, et al. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J Am Coll Cardiol. 2003;42(4):680\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"890_CR19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"SE Nissen","year":"2004","unstructured":"\u2022\u2022 Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071\u201380 In this landmark study, intensive lipid-lowering treatment with 80mg atorvastatin reduced progression of coronary atherosclerosis compared with pravastatin in patients with coronary artery disease.","journal-title":"JAMA"},{"issue":"13","key":"890_CR20","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","volume":"295","author":"SE Nissen","year":"2006","unstructured":"\u2022\u2022 Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556\u201365 This study showed, for the first time, that very intensive cholesterol lowering with 40 mg rosuvastatin can even regress atherosclerosis.","journal-title":"JAMA"},{"key":"890_CR21","unstructured":"\u2022\u2022 Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078\u201387 Maximal doses of rosuvastatin and atorvastatin led to significant and similar degree regression of coronary atherosclerosis, despite the lower level of LDL cholesterol and the higher level of HDL cholesterol with rosuvastatin therapy."},{"issue":"12","key":"890_CR22","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.jacc.2004.09.081","volume":"45","author":"M Kawasaki","year":"2005","unstructured":"Kawasaki M, Sano K, Okubo M, Yokoyama H, Ito Y, Murata I, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol. 2005;45(12):1946\u201353.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"890_CR23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/eurheartj\/ehu373","volume":"36","author":"L Raber","year":"2014","unstructured":"\u2022 Raber L, Taniwaki M, Zaugg S, Kelbaek H, Roffi M, Holmvang L, et al. Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. Eur Heart J. 2014;36(8):490\u2013500 Despite significant atheroma regression, no change in VH-IVUS defined per cent necrotic core was observed in patients with STEMI and treated with 40 mg rosuvastatin.","journal-title":"Eur Heart J"},{"issue":"4","key":"890_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ehjci\/jet251","volume":"15","author":"R Puri","year":"2014","unstructured":"Puri R, Libby P, Nissen SE, Wolski K, Ballantyne CM, Barter PJ, et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014;15(4):380\u20138.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"890_CR25","doi-asserted-by":"crossref","unstructured":"Kilic ID, Caiazzo G, Fabris E, Serdoz R, Abou-Sherif S, Madden S, et al. Near-infrared spectroscopy-intravascular ultrasound: Scientific basis and clinical applications. Eur Heart J Cardiovasc Imaging. 2015;16(12):1299\u2013306.","DOI":"10.1093\/ehjci\/jev208"},{"key":"890_CR26","doi-asserted-by":"crossref","unstructured":"Waksman R, Di Mario C, Torguson R, Ali ZA, Singh V, Skinner WH, et al. Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study. Lancet. 2019;394(10209):1629\u20131637.","DOI":"10.1016\/S0140-6736(19)31794-5"},{"issue":"1","key":"890_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jacc.2013.03.058","volume":"62","author":"AS Kini","year":"2013","unstructured":"\u2022 Kini AS, Baber U, Kovacic JC, Limaye A, Ali ZA, Sweeny J, et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013;62(1):21\u20139 Even after a short term intensive statin therapy a significant reduction in the plaque lipid composition was demonstrated with NIRS.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"890_CR28","doi-asserted-by":"publisher","first-page":"734","DOI":"10.4244\/EIJV12I6A118","volume":"12","author":"RM Oemrawsingh","year":"2016","unstructured":"Oemrawsingh RM, Garcia-Garcia HM, van Geuns RJM, Lenzen MJ, Simsek C, de Boer SPM, et al. Integrated biomarker and imaging study 3 (IBIS-3) to assess the ability of rosuvastatin to decrease necrotic core in coronary arteries. EuroIntervention. 2016;12(6):734\u20139.","journal-title":"EuroIntervention."},{"issue":"13","key":"890_CR29","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jacc.2015.01.036","volume":"65","author":"R Puri","year":"2015","unstructured":"Puri R, Nicholls SJ, Shao M, Kataoka Y, Uno K, Kapadia SR, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65(13):1273\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"890_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.atherosclerosis.2008.05.014","volume":"202","author":"S Takarada","year":"2009","unstructured":"Takarada S, Imanishi T, Kubo T, Tanimoto T, Kitabata H, Nakamura N, et al. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis. 2009;202(2):491\u20137.","journal-title":"Atherosclerosis."},{"issue":"21","key":"890_CR31","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1016\/j.jacc.2014.08.045","volume":"64","author":"K Komukai","year":"2014","unstructured":"Komukai K, Kubo T, Kitabata H, Matsuo Y, Ozaki Y, Takarada S, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography. J Am Coll Cardiol. 2014;64(21):2207\u201317.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"890_CR32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jacc.2016.10.028","volume":"69","author":"AS Kini","year":"2016","unstructured":"\u2022 Kini AS, Vengrenyuk Y, Yoshimura T, Matsumura M, Pena J, Baber U, et al. Assessment of fibrous cap thickness by optical coherence tomography in vivo: reproducibility and standardization. J Am Coll Cardiol. 2016;69(6):644\u201357 Baseline Fibrous cap thickness significantly increased upon follow-up with 8\u201312 weeks of 40 mg rosuvastatin therapy.","journal-title":"J Am Coll Cardiol"},{"key":"890_CR33","doi-asserted-by":"crossref","unstructured":"Bergeron N, Phan BAP, Ding Y, Fong A, Krauss RM. Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibition. Circulation. 2015;132(17):1648\u201366.","DOI":"10.1161\/CIRCULATIONAHA.115.016080"},{"issue":"16","key":"890_CR34","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","volume":"62","author":"D Urban","year":"2013","unstructured":"Urban D, P\u00f6ss J, B\u00f6hm M, Laufs U. Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62(16):1401\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"890_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","volume":"248","author":"JM Cheng","year":"2016","unstructured":"Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Boersma E, van Geuns R-J, Serruys PW, et al. PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2016;248:117\u201322.","journal-title":"Atherosclerosis."},{"key":"890_CR36","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients. JAMA. 2016;316(22):2373\u20132384. Addition of evolocumab to statin therapy resulted in greater LDL - cholesterol lowering and atheroma regression compared to statins alone.","DOI":"10.1001\/jama.2016.16951"},{"issue":"15","key":"890_CR37","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/0002-9149(91)90924-A","volume":"67","author":"JJ Genest","year":"1991","unstructured":"Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 1991;67(15):1185\u20139.","journal-title":"Am J Cardiol"},{"issue":"Suppl","key":"890_CR38","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/0021-9150(96)05852-2","volume":"124","author":"G Assmann","year":"1996","unstructured":"Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124(Suppl):S11\u201320.","journal-title":"Atherosclerosis"},{"key":"890_CR39","doi-asserted-by":"crossref","unstructured":"Puri R, Nissen SE, Shao M, Kataoka Y, Uno K, Kapadia SR, et al. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: implications for coronary atheroma progression and cardiovascular events. Eur J Prev Cardiol. 2016;23(5):474\u201385.","DOI":"10.1177\/2047487315572920"},{"issue":"17","key":"890_CR40","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","volume":"290","author":"SE Nissen","year":"2003","unstructured":"Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290(17):2292\u2013300.","journal-title":"JAMA."},{"issue":"25","key":"890_CR41","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1161\/hc2501.092494","volume":"103","author":"PK Shah","year":"2001","unstructured":"Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, et al. High-dose recombinant apolipoprotein A-I(Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation. 2001;103(25):3047\u201350.","journal-title":"Circulation."},{"issue":"5","key":"890_CR42","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jacc.2005.11.040","volume":"47","author":"SJ Nicholls","year":"2006","unstructured":"Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S, et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol. 2006;47(5):992\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"890_CR43","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1056\/NEJMoa070635","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Tardif J-C, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304\u201316.","journal-title":"N Engl J Med"},{"issue":"21","key":"890_CR44","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109\u201322.","journal-title":"N Engl J Med"},{"issue":"24","key":"890_CR45","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.108.790733","volume":"118","author":"SJ Nicholls","year":"2008","unstructured":"Nicholls SJ, Tuzcu EM, Brennan DM, Tardif J-C, Nissen SE. Cholesteryl Ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE investigation of lipid level management using coronary ultrasound to assess reduction of Atherosclerosi. Circulation. 2008;118(24):2506\u201314.","journal-title":"Circulation."},{"issue":"46","key":"890_CR46","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","volume":"35","author":"J-C Tardif","year":"2014","unstructured":"Tardif J-C, Ballantyne CM, Barter P, Dasseux J-L, Fayad ZA, Guertin M-C, et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial\u2020. Eur Heart J. 2014;35(46):3277\u201386.","journal-title":"Eur Heart J"},{"issue":"2","key":"890_CR47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0735-1097(02)01955-1","volume":"40","author":"M Matsuzaki","year":"2002","unstructured":"Matsuzaki M, Hiramori K, Imaizumi T, Kitabatake A, Hishida H, Nomura M, et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the low density lipoprotein-apheresis coronary morphology and reserve trial (LACMART). J Am Coll Cardiol. 2002;40(2):220\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"890_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcme.2014.03.001","volume":"3","author":"N Nakajima","year":"2014","unstructured":"Nakajima N, Miyauchi K, Yokoyama T, Ogita M, Miyazaki T, Tamura H, et al. Effect of combination of ezetimibe and a statin on coronary plaque regression in patients with acute coronary syndrome. IJC Metab Endocr. 2014;3:8\u201313.","journal-title":"IJC Metab Endocr"},{"key":"890_CR49","doi-asserted-by":"crossref","unstructured":"Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Plaque REgression with cholesterol absorption inhibitor or synthesis inhibitor evaluated by IntraVascular UltraSound (PRECISE-IVUS trial): study protocol for a randomized controlled trial. J Cardiol 2015","DOI":"10.1016\/j.jjcc.2014.12.011"},{"issue":"21","key":"890_CR50","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1161\/01.CIR.0000147777.12010.EF","volume":"110","author":"J-C Tardif","year":"2004","unstructured":"Tardif J-C, Gr\u00e9goire J, L\u2019Allier PL, Anderson TJ, Bertrand O, Reeves F, et al. Effects of the acyl coenzyme a:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation. 2004;110(21):3372\u20137.","journal-title":"Circulation."},{"issue":"12","key":"890_CR51","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMoa054699","volume":"354","author":"SE Nissen","year":"2006","unstructured":"Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006;354(12):1253\u201363.","journal-title":"N Engl J Med"},{"issue":"13","key":"890_CR52","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561\u201373.","journal-title":"JAMA."},{"issue":"1","key":"890_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12933-017-0533-7","volume":"16","author":"MW Kennedy","year":"2017","unstructured":"Kennedy MW, Fabris E, Suryapranata H, Kedhi E. Is ischemia the only factor predicting cardiovascular outcomes in all diabetes mellitus patients? Cardiovasc Diabetol. 2017;16(1):51.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"890_CR54","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.amjcard.2016.07.059","volume":"118","author":"MW Kennedy","year":"2016","unstructured":"Kennedy MW, Hermanides RS, Kaplan E, Hemradj V, Fabris E, Koopmans PC, et al. Fractional flow reserve\u2013guided deferred versus complete revascularization in patients with diabetes mellitus. Am J Cardiol. 2016;118(9):1293\u20139.","journal-title":"Am J Cardiol"},{"key":"890_CR55","doi-asserted-by":"crossref","unstructured":"Kennedy MW, Fabris E, Ijsselmuiden AJ, Nef H, Reith S, Escaned J, et al. Combined optical coherence tomography morphologic and fractional flow reserve hemodynamic assessment of non- culprit lesions to better predict adverse event outcomes in diabetes mellitus patients: COMBINE (OCT-FFR) prospective study. Rationale and design. Cardiovasc Diabetol. 2016;15(1):144.","DOI":"10.1186\/s12933-016-0464-8"},{"issue":"18","key":"890_CR56","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217\u201325.","journal-title":"JAMA."},{"issue":"13","key":"890_CR57","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen SE, Nicholls SJ, Wolski K, Rod\u00e9s-Cabau J, Cannon CP, Deanfield JE, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008;299(13):1547\u201360.","journal-title":"JAMA."},{"issue":"11","key":"890_CR58","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.108.771899","volume":"118","author":"PW Serruys","year":"2008","unstructured":"Serruys PW, Garc\u00eda-Garc\u00eda HM, Buszman P, Erne P, Verheye S, Aschermann M, et al. Effects of the direct lipoprotein-associated phospholipase a(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118(11):1172\u201382.","journal-title":"Circulation."},{"issue":"18","key":"890_CR59","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","volume":"370","author":"HD White","year":"2014","unstructured":"White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702\u201311.","journal-title":"N Engl J Med"},{"issue":"10","key":"890_CR60","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","volume":"312","author":"ML O\u2019Donoghue","year":"2014","unstructured":"O\u2019Donoghue ML, Braunwald E, White HD, Steen DP, Lukas MA, Tarka E, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312(10):1006\u201315.","journal-title":"JAMA."},{"issue":"8","key":"890_CR61","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4244\/EIJV8I8A144","volume":"8","author":"JJ Wykrzykowska","year":"2012","unstructured":"Wykrzykowska JJ, Diletti R, Gutierrez-Chico JL, van Geuns RJ, van der Giessen WJ, Ramcharitar S, et al. Plaque sealing and passivation with a mechanical self-expanding low outward force nitinol vShield device for the treatment of IVUS and OCT-derived thin cap fibroatheromas (TCFAs) in native coronary arteries: report of the pilot study vShield evaluated at. EuroIntervention. 2012;8(8):945\u201354.","journal-title":"EuroIntervention."},{"issue":"1","key":"890_CR62","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2011.12.008","volume":"221","author":"S Brugaletta","year":"2012","unstructured":"Brugaletta S, Radu MD, Garcia-Garcia HM, Heo JH, Farooq V, Girasis C, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis. 2012;221(1):106\u201312.","journal-title":"Atherosclerosis."},{"issue":"5","key":"890_CR63","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2125.2005.02435.x","volume":"59","author":"JK Aronson","year":"2005","unstructured":"Aronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharmacol. 2005;59(5):491\u20134.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"890_CR64","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/(SICI)1097-0304(199607)38:3<238::AID-CCD3>3.0.CO;2-9","volume":"38","author":"BW Batkoff","year":"1996","unstructured":"Batkoff BW, Linker DT. Safety of intracoronary ultrasound: data from a multicenter European registry. Catheter Cardiovasc Diagn. 1996;38(3):238\u201341.","journal-title":"Catheter Cardiovasc Diagn"},{"issue":"5","key":"890_CR65","doi-asserted-by":"publisher","first-page":"575","DOI":"10.4244\/EIJV6I5A97","volume":"6","author":"F Imola","year":"2010","unstructured":"Imola F, Mallus MT, Ramazzotti V, Manzoli A, Pappalardo A, Di Giorgio A, et al. Safety and feasibility of frequency domain optical coherence tomography to guide decision making in percutaneous coronary intervention. EuroIntervention. 2010;6(5):575\u201381.","journal-title":"EuroIntervention."},{"issue":"12","key":"890_CR66","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.jcmg.2013.09.014","volume":"6","author":"EA Osborn","year":"2013","unstructured":"Osborn EA, Jaffer FA. The advancing clinical impact of molecular imaging in CVD. JACC Cardiovasc Imaging. 2013;6(12):1327\u201341.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"18","key":"890_CR67","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1136\/heartjnl-2011-301370","volume":"100","author":"FA Jaffer","year":"2014","unstructured":"Jaffer FA, Verjans JW. Molecular imaging of atherosclerosis: clinical state-of-the-art. Heart. 2014;100(18):1469\u201377.","journal-title":"Heart."},{"issue":"84","key":"890_CR68","doi-asserted-by":"publisher","first-page":"84ra45","DOI":"10.1126\/scitranslmed.3001577","volume":"3","author":"C Vinegoni","year":"2011","unstructured":"Vinegoni C, Botnaru I, Aikawa E, Calfon MA, Iwamoto Y, Folco EJ, et al. Indocyanine green enables near-infrared fluorescence imaging of lipid-rich, inflamed atherosclerotic plaques. Sci Transl Med. 2011;3(84):84ra45.","journal-title":"Sci Transl Med"},{"issue":"9","key":"890_CR69","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jacc.2006.12.014","volume":"49","author":"BG Brown","year":"2007","unstructured":"Brown BG, Zhao X-Q. Is intravascular ultrasound the gold standard surrogate for clinically relevant atherosclerosis progression? J Am Coll Cardiol. 2007;49(9):933\u20138.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00890-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-020-00890-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00890-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T01:26:41Z","timestamp":1650245201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-020-00890-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":69,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["890"],"URL":"https:\/\/doi.org\/10.1007\/s11883-020-00890-4","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"16 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Di Mario reports grants from Infraredx, Medtronic, Abbott, Daiichi Sanyo and Shockwave outside the submitted work. Dr. Kedhi reports personal fees from Abbott and Medtronic outside the submitted work. All of the other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"76"}}